logo
  Join        Login             Stock Quote

Cubist (CBST) Posts Double-Digit Revenue Growth In Q4 On CUBICIN Strength

 January 07, 2013 07:28 AM
 


(By Balachander) Cubist Pharmaceuticals Inc. (NASDAQ: CBST) posted double-digit revenue increase for the fourth quarter boosted by continued growth of the company's bactericidal antibiotic CUBICIN (daptomycin for injection).

The Lexington, Massachusetts-based company's revenue for the fourth-quarter and full-year rose 16 percent and 23 percent, respectively.

Cubist said revenue was $245.9 million and $926.4 million for the three-month period and 2012, respectively.

Top-line numbers surrounded Wall Street consensus estimates.

U.S. CUBICIN revenue grew 14 percent to $216.0 million for the fourth quarter and 16 percent to $809.2 million for the 12 month period. International CUBICIN revenue also grew 34 percent and 38 percent for the same periods.

[Related -Cubist Pharmaceuticals Inc. (CBST): All-Time Highs On The Horizon?]

"As we enter 2013, and anticipate Phase 3 data for ceftolozane/tazobactam, we expect to begin the next significant chapter of Cubist's growth story," commented CEO Michael Bonney.

The company expects top-line data readouts from these two clinical trials are expected in the second-half of 2013.

"We are advancing three Phase 3 product candidates, including ceftolozane/tazobactam, which we believe has blockbuster potential based on its unique attributes and the significant need for new antibiotics to treat infections caused by multi-drug resistant Gram-negative pathogens," Bonney said.

The stock, which has been trading in the 52-week range of $36.73 to $49.86, ended at $43.21 on Friday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageThe Eurozone: On The Road To Recovery With A Lingering Risk

Back in September the idea that the Eurozone's economy could potentially undergo a recovery (see post) was read on...

article imageAversion to the Mean

Stocks’ gangbusters February doesn’t mean March must be a read on...

article imageNasdaq Back To 2000 Peak But What About Investors' Portfolios?

I hope Wall Street and CNBC don’t insult the intelligence of investors who were fully invested at the read on...

article imageStocks Break Out Again But May Be Running On Fumes

Despite low trading volume, a strong dollar, mixed economic and earnings reports, paralyzing weather read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.